TL;DR
This large-scale UK cohort study found that current smokers had a significantly lower risk of severe COVID-19 outcomes (hospitalization, ICU admission, and death) compared to never-smokers. However, this protective effect was not observed for e-cigarette users, and all-cause mortality remained higher in current smokers, suggesting complex interactions between smoking, nicotine, and the virus.
What Problem Does This Paper Address?
The early stages of the COVID-19 pandemic saw a prevailing assumption that smoking, a known risk factor for respiratory infections, would also worsen COVID-19 outcomes. However, emerging evidence began to suggest a counterintuitive protective effect of smoking against SARS-CoV-2 infection. This paper aims to rigorously investigate this association, specifically examining the relationship between current smoking, e-cigarette use, and severe COVID-19 outcomes (hospitalization, ICU admission, and death) in a large, representative community cohort. The study also seeks to understand if any observed protective effects are due to nicotine or other components of tobacco smoke, and to clarify the role of e-cigarette use, which has a less established link to respiratory health.
Methods
The researchers conducted an open cohort study using anonymized primary care records from 1205 general practices in England, representing approximately 20% of English practices. This dataset, covering 7,869,534 individuals, was linked to national data on COVID-19 PCR test results, hospital admissions (Hospital Episode Statistics - HES), intensive care unit (ICU) admissions (Intensive Care National Audit & Research Centre - ICNARC), and death certificates.
The primary analytical approach involved multivariable Cox proportional hazards models. These models were used to estimate hazard ratios (HRs) for the association between smoking status (never, former, light, moderate, heavy) and severe COVID-19 outcomes. The analysis involved sequential adjustment for potential confounders, including demographic factors (age, gender, socioeconomic status, ethnicity, region) and non-smoking-related diseases. Further adjustments were made for body mass index (BMI) and smoking-related diseases to isolate the direct causal path between smoking and severe COVID-19.
E-cigarette use was analyzed separately, with confounding controlled by demographic factors and smoking status. The study also examined all-cause mortality, considering the potential for smoking to influence overall mortality even if it reduced COVID-19-specific deaths.
Datasets
- QResearch Database: A large primary care database in England containing demographic information, smoking status, and diagnoses for approximately 20% of the English population.
- COVID-19 PCR Test Records: Data on positive SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) tests from Public Health England (PHE).
- Hospital Episode Statistics (HES): National data on hospital admissions in England.
- Intensive Care National Audit & Research Centre (ICNARC) Case Mix Programme: Data on ICU admissions in England.
- Death Certificates: National data on deaths in England, including cause and date, provided by the Office for National Statistics.
Key Insights and Ideas
- The "Smoker's Paradox" in COVID-19: The most striking finding is the consistent association between current smoking and a reduced risk of severe COVID-19 outcomes. This challenges initial assumptions and suggests that components within tobacco smoke may offer some protection against SARS-CoV-2 infection or its severe manifestations.
- Nicotine as a Potential Culprit: While the study doesn't definitively prove it, nicotine is highlighted as a plausible candidate for this protective effect, given its known anti-inflammatory properties and interactions with immune pathways. This opens avenues for exploring nicotine-based therapies for COVID-19.
- E-cigarettes: An Unclear Picture: Unlike traditional smoking, e-cigarette use showed no clear association with severe COVID-19 outcomes. This suggests that the protective mechanisms, if any, are specific to the complex mixture of chemicals in tobacco smoke rather than just nicotine delivery.
- The Double-Edged Sword of Smoking: Despite the apparent reduction in COVID-19 severity, current smokers still faced higher all-cause mortality. This underscores that the overall health risks of smoking far outweigh any potential COVID-19-related benefits, reinforcing the importance of quitting.
- Former Smokers at Higher Risk: Individuals who had previously smoked were found to have a higher risk of severe COVID-19, suggesting that the protective effect might be transient or related to active smoking.
Key Results
- Hospitalization: Compared to never-smokers, current smokers had a significantly lower risk of COVID-19 hospitalization. Adjusted hazard ratios (HRs) ranged from 0.49 to 0.64 across different smoking intensity levels.
- ICU Admission: The reduction in risk for ICU admission was even more pronounced, with HRs ranging from 0.15 to 0.35 for current smokers.
- Death from COVID-19: Current smokers also had a reduced risk of death from COVID-19, with HRs ranging from 0.66 to 0.79.
- Former Smokers: Former smokers had a higher risk of severe COVID-19, with HRs for hospitalization, ICU admission, and death ranging from 1.07 to 1.17.
- E-cigarette Use: The association between e-cigarette use and severe COVID-19 outcomes was unclear, with HRs close to 1 and wide confidence intervals, indicating imprecision.
- All-Cause Mortality: Current smokers had a significantly higher risk of all-cause mortality (HR = 1.42) compared to never-smokers, even during the COVID-19 epidemic.
Limitations and Future Work
- E-cigarette Underestimation: The study acknowledges that e-cigarette use might have been underestimated in GP records, potentially affecting the precision of findings related to vaping.
- Vaping Status Recording: Vaping status was recorded a median of 23 months prior to the study start, and a significant proportion of initial e-cigarette users may have ceased use, potentially diluting any observed protective effect.
- Confounding by Behavior: While efforts were made to control for confounders, the authors note that people who smoke might have adopted more rigorous social distancing behaviors, which could influence outcomes.
- Observational Nature: As an observational study, it cannot definitively establish causality.
- Future Work: The findings support further investigation into the protective mechanisms of smoking for SARS-CoV-2 infection, particularly the role of nicotine. The authors suggest ongoing trials of nicotine as a potential treatment for COVID-19. Further research is also needed to clarify the role of e-cigarette use and to confirm the exploratory findings on effect modification by age, gender, ethnicity, and airways disease.
Summary updated